<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8907422</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6565</journal-id>
<journal-id journal-id-type="nlm-ta">Pharmacol Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacol. Res.</journal-id>
<journal-title-group>
<journal-title>Pharmacological research</journal-title>
</journal-title-group>
<issn pub-type="ppub">1043-6618</issn>
<issn pub-type="epub">1096-1186</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30009933</article-id>
<article-id pub-id-type="pmc">6345621</article-id>
<article-id pub-id-type="doi">10.1016/j.phrs.2018.07.010</article-id>
<article-id pub-id-type="manuscript">NIHMS1500914</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Extreme Enhancement or Depletion of Serotonin Transporter Function and Serotonin Availability in Autism Spectrum Disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Garbarino</surname>
<given-names>Valentina R.</given-names>
</name>
<!--<email>garbarino@livemail.uthscsa.edu</email>-->
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gilman</surname>
<given-names>T. Lee</given-names>
</name>
<!--<email>gilmant@uthscsa.edu</email>-->
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Daws</surname>
<given-names>Lynette C.</given-names>
</name>
<!--<email>daws@uthscsa.edu</email>-->
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gould</surname>
<given-names>Georgianna G.</given-names>
</name>
<!--<email>gouldg@uthscsa.edu</email>-->
<xref ref-type="corresp" rid="CR1">*</xref>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Department of Cellular and Integrative Physiology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.</aff>
<aff id="A2"><label>b</label>The Sam and Ann Barshop Institute for Longevity and Aging Studies, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.</aff>
<aff id="A3"><label>c</label>Addiction Research, Treatment &amp; Training Center of Excellence, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.</aff>
<aff id="A4"><label>d</label>Department of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.</aff>
<aff id="A5"><label>e</label>Center for Biomedical Neuroscience, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.</aff>
<author-notes>
<corresp id="CR1"><label>*</label><bold>Corresponding author</bold>: Georgianna G. Gould, The University of Texas Health Science Center at San Antonio, MS 7756, Department of Cellular and Integrative Physiology, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, PH: 210-567-4302 Fax: 210-567-4410</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P55"><bold>Conflict of Interest</bold> Statement:</p>
<p id="P56">None of the authors have any conflicts of interest to report.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>26</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2020</year>
</pub-date>
<volume>140</volume>
<fpage>85</fpage>
<lpage>99</lpage>
<!--elocation-id from pubmed: 10.1016/j.phrs.2018.07.010-->
<abstract id="ABS1">
<p id="P1">A variety of human and animal studies support the hypothesis that serotonin (5-hydroxytryptamine or 5-HT) system dysfunction is a contributing factor to the development of autism in some patients. However, many questions remain about how developmental manipulation of various components that influence 5-HT signaling (5-HT synthesis, transport, metabolism) persistently impair social behaviors. This review will summarize key aspects of central 5-HT function important for normal brain development, and review evidence implicating perinatal disruptions in 5-HT signaling in the pathophysiology of autism spectrum disorder. We discuss the importance, and relative dearth, of studies that explore the possible correlation to autism in the interactions between important intrinsic and extrinsic factors that may disrupt 5-HT homeostasis during development. In particular, we focus on exposure to 5-HT transport altering mechanisms such as selective serotonin-reuptake inhibitors or genetic polymorphisms in primary or auxiliary transporters of 5-HT, and how they relate to neurological stores of serotonin and its precursors. A deeper understanding of the many mechanisms by which 5-HT signaling can be disrupted, alone and in concert, may contribute to an improved understanding of the etiologies and heterogeneous nature of this disorder. We postulate that extreme bidirectional perturbations of these factors during development likely compound or synergize to facilitate enduring neurochemical changes resulting in insufficient or excessive 5-HT signaling, that could underlie the persistent behavioral characteristics of autism spectrum disorder.</p>
</abstract>
<abstract abstract-type="graphical" id="ABS2">
<title>Graphical abstract</title>
<p id="P2"><bold>Abstract Summary Figure:</bold> Multiple factors in serotonin (5-hydroxytryptamine, 5-HT) signaling are hypothesized to influence autism spectrum disorder (ASD) etiologies by cumulatively producing excessive increases or decreases in 5-HT levels during critical developmental stages. In adults, 5-HT availability and demand are influenced by availability of the 5-HT precursor L-tryptophan (TRP), as well as by use of medications and/or functional polymorphisms that influence 5-HT signaling and metabolism (e.g., the 5-HT transporter-linked polymorphic region, 5-HTTLPR). During fetal development, maternal TRP is a rate-limiting factor in fetal 5-HT synthesis. Adulthood dietary TRP restriction or supplementation can produce measurable, but transient, behavioral consequences. Contrastingly, such changes in the fetal environment can disturb fetal growth and neurodevelopment, resulting in enduring impairments for the lifetime of the individual. We hypothesize that some of the behavioral heterogeneity observed in the autistic population is attributable to <italic>combined</italic> effects of several neurodevelopmental factors affecting 5-HT system function, rather than aberration of a single component.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorder</kwd>
<kwd>neurodevelopment</kwd>
<kwd>serotonin homeostasis</kwd>
<kwd>selective serotonin reuptake inhibitors</kwd>
<kwd>serotonin transporter</kwd>
<kwd>tryptophan</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>